Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Zhuo Fu, Yongsheng Xu & Chunquan Cai. (2021) Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis. Journal of Asthma 58:10, pages 1350-1358.
Read now
Read now
Nidhya Navanandan & Stanley J. Szefler. (2020) Personalized asthma management in pediatric patients based on treatment response. Expert Review of Precision Medicine and Drug Development 5:6, pages 439-446.
Read now
Read now
Federica Porcaro, Renato Cutrera & Giovanni Battista Pajno. (2019) Options of immunotherapeutic treatments for children with asthma. Expert Review of Respiratory Medicine 13:10, pages 937-949.
Read now
Read now
Miguel Tortajada-Girbés, Rosa Bousquet, Montserrat Bosque, Jesús Joaquín Carrera Martínez, María Dolores Ibáñez, Ana Moreira, Antonio Nieto, Ana María Plaza, Cristina Rivas, Gloria Requena, Manuel Sánchez-Solis, Ana Tabar, Javier Torres-Borrego & Lydia Zapatero. (2018) Efficacy and effectiveness of omalizumab in the treatment of childhood asthma. Expert Review of Respiratory Medicine 12:9, pages 745-754.
Read now
Read now
Désirée Larenas-Linnemann, Antonio Nieto, Oscar Palomares, Paulo Márcio Pitrez & Gherson Cukier. (2018) Moving toward consensus on diagnosis and management of severe asthma in children. Current Medical Research and Opinion 34:3, pages 447-458.
Read now
Read now
J. Mark FitzGerald, Catherine Lemiere, M. Diane Lougheed, Francine M. Ducharme, Sharon D. Dell, Clare Ramsey, M. Connie L. Yang, Andréanne Côté, Wade Watson, Ron Olivenstein, Anne Van Dam, Cristina Villa-Roel & Roland Grad. (2017) Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 1:4, pages 199-221.
Read now
Read now
Maxime Luu, Marc Bardou, Philippe Bonniaud & Françoise Goirand. (2016) Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1503-1511.
Read now
Read now
Ciro Romano. (2015) Omalizumab therapy for children and adolescents with severe allergic asthma. Expert Review of Clinical Immunology 11:12, pages 1309-1319.
Read now
Read now
Robert G Townley, Swati Agrawal & Kiran Sapkota. (2010) Omalizumab for pediatric asthma. Expert Opinion on Biological Therapy 10:11, pages 1595-1608.
Read now
Read now
Articles from other publishers (50)
Francesca Galletta, Lucia Caminiti, Cecilia Lugarà, Simone Foti Randazzese, Paolo Barraco, Federica D’Amico, Pierangela Irrera, Giuseppe Crisafulli & Sara Manti. (2023) Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life. Journal of Personalized Medicine 13:7, pages 1068.
Crossref
Crossref
Grazia Fenu, Andrea La Tessa, Claudia Calogero & Enrico Lombardi. (2023) Severe pediatric asthma therapy: Omalizumab—A systematic review and meta-analysis of efficacy and safety profile. Frontiers in Pediatrics 10.
Crossref
Crossref
Hugo A Farne, Amanda Wilson, Stephen Milan, Emma Banchoff, Freda Yang & Colin VE Powell. (2022) Anti-IL-5 therapies for asthma. Cochrane Database of Systematic Reviews 2022:7.
Crossref
Crossref
Joanne Martin, Jennifer Townshend & Malcolm Brodlie. (2022) Diagnosis and management of asthma in children. BMJ Paediatrics Open 6:1, pages e001277.
Crossref
Crossref
Ling Liu, Pengxiang Zhou, Zhenhuan Wang, Suodi Zhai & Wei Zhou. (2022) Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis. Frontiers in Pediatrics 10.
Crossref
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Lu Cheng, Tianrui Yang, Xiang Ma, Yuling Han & Yongtai Wang. (2021) Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With Moderate-To-Severe Asthma. Journal of Pharmacy Practice, pages 089719002110382.
Crossref
Crossref
Noriko Nakamura, Yuka Kashitani, Hajime Yoshisue, Makoto Nagasaki & Takayoshi Sasajima. (2021) Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance. Allergology International 70:3, pages 319-326.
Crossref
Crossref
Coco Dekkers, Mehran Alizadeh Aghdam, Marlies Graaf, André C. Knulst, Yolanda Meijer, Juul M. P.A. Reek, Marike B. Stadermann & Heike Röckmann. (2021) Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatric Allergy and Immunology 32:4, pages 720-726.
Crossref
Crossref
Jessica Purizaca-Bazán & José Antonio Ortega-Martell. (2020) Bloqueo de inmunoglobulina E en el asma grave. Revista Alergia México 67.
Crossref
Crossref
Daniel P. Henriksen, Uffe Bodtger, Kirsten Sidenius, Niels Maltbaek, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Ole Norgaard, Louise K. Madsen & Bo L. Chawes. (2020) Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy, Asthma & Clinical Immunology 16:1.
Crossref
Crossref
Stanley J. Szefler, Thomas B. Casale, Tmirah Haselkorn, Bongin Yoo, Benjamin Ortiz, Meyer Kattan & William W. Busse. (2020) Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. The Journal of Allergy and Clinical Immunology: In Practice 8:8, pages 2673-2680.e3.
Crossref
Crossref
Katherine L. Tison, Meera Patrawala & Michael S. Blaiss. (2020) Monoclonal Antibody Therapy in Childhood Asthma. Current Allergy and Asthma Reports 20:7.
Crossref
Crossref
Ioana Agache, Claudio Rocha, Jessica Beltran, Yang Song, Margarita Posso, Ivan Solà, Pablo Alonso‐Coello, Cezmi Akdis, Mubeccel Akdis, Giorgio W. Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández Martín, Parameswaran Nair, Liam O'Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae‐Sim Park, Luis Pérez de Llano, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Carlos Canelo‐Aybar, Oscar Palomares & Marek Jutel. (2020) Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 75:5, pages 1043-1057.
Crossref
Crossref
Steve Chaplin. (2020) Monoclonal antibodies for the treatment of severe asthma. Prescriber 31:3, pages 23-28.
Crossref
Crossref
Stephanie Lovinsky‐Desir. (2019) The use of biologic therapies for the management of pediatric asthma. Pediatric Pulmonology 55:3, pages 803-808.
Crossref
Crossref
Giuseppe Crisafulli, Lucia Caminiti, Fernanda Chiera, Stefania Arasi, Giuseppina Salzano, Ilenia Panasiti, Andrea Barbalace & Giovanni Battista Pajno. (2019) Omalizumab in children with severe allergic disease: a case series. Italian Journal of Pediatrics 45:1.
Crossref
Crossref
Sy Duong-Quy & Krista Todoric. 2018. Allergy and Asthma. Allergy and Asthma
1
47
.
Sy Duong-Quy & Krista Todoric. 2019. Allergy and Asthma. Allergy and Asthma
305
351
.
Jocelyne Just, Antoine Deschildre, Stéphanie Lejeune & Flore Amat. (2018) New perspectives of childhood asthma treatment with biologics. Pediatric Allergy and Immunology.
Crossref
Crossref
Bradley E. Chipps, Leonard B. Bacharier, Judith R. Farrar, Daniel J. Jackson, Kevin R. Murphy, Wanda Phipatanakul, Stanley J. Szefler, W. Gerald Teague & Robert S. Zeiger. (2018) The pediatric asthma yardstick. Annals of Allergy, Asthma & Immunology 120:6, pages 559-579.e11.
Crossref
Crossref
Marc Humbert, Camille Taillé, Laurence Mala, Vincent Le Gros, Jocelyne Just & Mathieu Molimard. (2018) Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. European Respiratory Journal 51:5, pages 1702523.
Crossref
Crossref
Ian D Pavord, Richard Beasley, Alvar Agusti, Gary P Anderson, Elisabeth Bel, Guy Brusselle, Paul Cullinan, Adnan Custovic, Francine M Ducharme, John V Fahy, Urs Frey, Peter Gibson, Liam G Heaney, Patrick G Holt, Marc Humbert, Clare M Lloyd, Guy Marks, Fernando D Martinez, Peter D Sly, Erika von Mutius, Sally Wenzel, Heather J Zar & Andy Bush. (2018) After asthma: redefining airways diseases. The Lancet 391:10118, pages 350-400.
Crossref
Crossref
Hugo A Farne, Amanda Wilson, Colin Powell, Lynne Bax & Stephen J Milan. (2017) Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Óscar Palomares, Silvia Sánchez-Ramón, Ignacio Dávila, Luis Prieto, Luis Pérez de Llano, Marta Lleonart, Christian Domingo & Antonio Nieto. (2017) dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. International Journal of Molecular Sciences 18:6, pages 1328.
Crossref
Crossref
Bradley E. Chipps, Bob Lanier, Henry Milgrom, Antoine Deschildre, Gunilla Hedlin, Stanley J. Szefler, Meyer Kattan, Farid Kianifard, Benjamin Ortiz, Tmirah Haselkorn, Ahmar Iqbal, Karin Rosén, Benjamin Trzaskoma & William W. Busse. (2017) Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. Journal of Allergy and Clinical Immunology 139:5, pages 1431-1444.
Crossref
Crossref
Hiroshi Odajima, Motohiro Ebisawa, Toshikazu Nagakura, Takao Fujisawa, Akira Akasawa, Komei Ito, Satoru Doi, Koichi Yamaguchi, Toshio Katsunuma, Kazuyuki Kurihara, Takahide Teramoto, Kazuko Sugai, Mitsuhiko Nambu, Akira Hoshioka, Shigemi Yoshihara, Norio Sato, Noriko Seko & Sankei Nishima. (2017) Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergology International 66:1, pages 106-115.
Crossref
Crossref
Tugba Songul Tat & Aykut Cilli. (2016) Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. Annals of Allergy, Asthma & Immunology 117:5, pages 546-549.
Crossref
Crossref
Hideki Yoshikawa, Mihoko Iwata, Hiroshi Matsuzaki, Rintaro Ono, Yoko Murakami, Naohiko Taba, Satoshi Honjo, Chikako Motomura & Hiroshi Odajima. (2016) Impact of omalizumab on medical cost of childhood asthma in Japan. Pediatrics International 58:5, pages 425-428.
Crossref
Crossref
A.M. Plaza, M.D.P. Ibáñez, M. Sánchez-Solís, M. Bosque-García, M.J. Cabero, J.L. Corzo, G. García-Hernández, B. de la Hoz, J. Korta-Murua, C. Sánchez-Salguero, J. Torres-Borrego, M. Tortajada-Girbés, J. Valverde-Molina, L. Zapatero & A. Nieto. (2016) Consenso para el abordaje del asma grave pediátrica en la práctica clínica habitual. Anales de Pediatría 84:2, pages 122.e1-122.e11.
Crossref
Crossref
A.M. Plaza, M.D.P. Ibáñez, M. Sánchez-Solís, M. Bosque-García, M.J. Cabero, J.L. Corzo, G. García-Hernández, B. de la Hoz, J. Korta-Murua, C. Sánchez-Salguero, J. Torres-Borrego, M. Tortajada-Girbés, J. Valverde-Molina, L. Zapatero & A. Nieto. (2016) Consensus-based approach for severe paediatric asthma in routine clinical practice. Anales de Pediatría (English Edition) 84:2, pages 122.e1-122.e11.
Crossref
Crossref
Hiroshi Odajima, Motohiro Ebisawa, Toshikazu Nagakura, Takao Fujisawa, Akira Akasawa, Komei Ito, Satoru Doi, Koichi Yamaguchi, Toshio Katsunuma, Kazuyuki Kurihara, Naomi Kondo, Kazuko Sugai, Mitsuhiko Nambu, Akira Hoshioka, Shigemi Yoshihara, Norio Sato, Noriko Seko & Sankei Nishima. (2015) Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergology International 64:4, pages 364-370.
Crossref
Crossref
Antoine Deschildre, Christophe Marguet, Carole Langlois, Isabelle Pin, Jean-Luc Rittié, Jocelyne Derelle, Rola Abou Taam, Michael Fayon, Jacques Brouard, Jean Christophe Dubus, Daniel Siret, Laurence Weiss, Guillaume Pouessel, Laurent Beghin & Jocelyne Just. (2015) Real-life long-term omalizumab therapy in children with severe allergic asthma. European Respiratory Journal 46:3, pages 856-859.
Crossref
Crossref
Colin Powell, Stephen J Milan, Kerry Dwan, Lynne Bax & Nicola Walters. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Tianwen Lai, Shaobin Wang, Zhiwei Xu, Chao Zhang, Yun Zhao, Yue Hu, Chao Cao, Songmin Ying, Zhihua Chen, Wen Li, Bin Wu & Huahao Shen. (2015) Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific Reports 5:1.
Crossref
Crossref
Amelia Licari, Alessia Marseglia, Silvia Caimmi, Riccardo Castagnoli, Thomas Foiadelli, Salvatore Barberi & Gian Luigi Marseglia. (2014) Omalizumab in Children. Pediatric Drugs 16:6, pages 491-502.
Crossref
Crossref
Judy Pitts & Shahid I. Sheikh. (2014) Role of Omalizumab in Children With Difficult to Control Asthma. Clinical Pulmonary Medicine 21:6, pages 247-250.
Crossref
Crossref
Josef Riedler. (2014) Pediatric Asthma - do we need more innovation for treatment?. Pediatric Allergy and Immunology 25:1, pages 19-20.
Crossref
Crossref
Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters & Parameswaran Nair. (2014) Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews.
Crossref
Crossref
G.-J. Braunstahl, C.-W. Chen, R. Maykut, P. Georgiou, G. Peachey & J. Bruce. (2013) The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma. Respiratory Medicine 107:8, pages 1141-1151.
Crossref
Crossref
Paul D. Robinson & Peter Van Asperen. (2013) Newer Treatments in the Management of Pediatric Asthma. Pediatric Drugs 15:4, pages 291-302.
Crossref
Crossref
Kate McKeage. (2013) Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma. Drugs 73:11, pages 1197-1212.
Crossref
Crossref
Nicola A. Hanania, Sally Wenzel, Karin Rosén, Hsin-Ju Hsieh, Sofia Mosesova, David F. Choy, Preeti Lal, Joseph R. Arron, Jeffrey M. Harris & William Busse. (2013) Exploring the Effects of Omalizumab in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine 187:8, pages 804-811.
Crossref
Crossref
H. Pite, Â. Gaspar, M. Paiva & P. Leiria-Pinto. (2013) Omalizumab under 12 years old: Real-life practice. Allergologia et Immunopathologia 41:2, pages 133-136.
Crossref
Crossref
Jayesh Bhatt, Harish Vyas & Debra Forster. 2012. Children's Respiratory Nursing. Children's Respiratory Nursing
113
133
.
William Busse, Roland Buhl, Carlos Fernandez Vidaurre, Martin Blogg, Jin Zhu, Mark D. Eisner & Janice Canvin. (2012) Omalizumab and the risk of malignancy: Results from a pooled analysis. Journal of Allergy and Clinical Immunology 129:4, pages 983-989.e6.
Crossref
Crossref
M. Weinberger. (2011) Omalizumab (anti-IgE) for Asthma in Inner-City Children. AAP Grand Rounds 26:2, pages 18-18.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Allergy & Clinical Immunology 11:2, pages 150-156.
Crossref
Crossref
. (2010) Current World Literature. Current Opinion in Pediatrics 22:6, pages 833-842.
Crossref
Crossref
Ari J Fried & Hans C Oettgen. (2010) Anti-IgE in the treatment of allergic disorders in pediatrics. Current Opinion in Pediatrics 22:6, pages 758-764.
Crossref
Crossref